↓ Skip to main content

Tissue Agnostic Activity of BRAF plus MEK inhibitor in BRAF V600 mutant tumorsBRAF in nonmelanoma cancers

Overview of attention for article published in Molecular Cancer Therapeutics, April 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter
116 X users

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
21 Mendeley